Document:

Exhibit 10.1

 

THE
COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL
PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED
IN THIS EXHIBIT WITH “*****”.

 

FIRST AMENDMENT

 

TO THE LICENSE, MARKETING
AND DEVELOPMENT AGREEMENT

 

This
First Amendment (“First Amendment”) to the License,
Marketing and Development Agreement dated November
14, 2013 (the “Agreement”) is effective as of September 26, 2014 (the “First Amendment Effective
Date”), by and between Anthrogenesis Corporation, a Delaware corporation doing business as Celgene Cellular Therapeutics
(“CCT”), and Alliqua BioMedical, Inc., a Delaware corporation (formerly Alliqua, Inc., a Florida corporation)
(“Alliqua”). Alliqua and CCT may each be referred to as a “Party” or collectively be referred
to as the “Parties”.

 

WHEREAS Alliqua and CCT entered into the
Agreement;

 

WHEREAS both Parties now wish to amend
the terms of the Agreement as further described in this First Amendment;

 

NOW and THEREFORE the Parties hereby
agrees as follows:

 

All capitalized terms used in this First
Amendment shall have the meaning ascribed to them in the Agreement, except as otherwise expressly stated herein.

 

		1.	As of the First Amendment Effective Date, the defined term “Field” in Article
1 (Definitions) of the Agreement shall be deleted and replaced in its entirety with the following definition: 

 

“Field” means
acute and chronic non-healing wounds: pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunnel/undermined
wounds, surgical wounds (donor sites/grafts, dehiscence), trauma wounds (abrasions, lacerations, second degree burns, and skin
tears), and draining wounds. With respect to Biovance, “Field” also means podiatric and orthopedic applications for
homologous uses that include the repair of damaged or inadequate tissue to provide functional support or reinforcement of tendon,
nerve, muscle and bone.

 

		2.	As of the First Amendment Effective Date, Schedule 7.2 (Milestone Payments) of the Agreement
shall be deleted and replaced in its entirety with Schedule 7.2 attached to this First Amendment. 

 

		3.	As of the First Amendment Effective Date, Section 7.2 of the Agreement shall be deleted
in its entirety and replaced with the following:

 

7.2Milestone Payments.
Alliqua shall make non-refundable, non-creditable milestone payments (each, a “Milestone Payment”) to CCT
upon the achievement of certain milestone events (each a “Milestone Event”) in connection with the sale of a
Licensed Product as set forth on Schedule 7.2 hereto, with the caveat that each individual Milestone Payment set forth in rows
numbered (1) through (11) of the table set forth on Schedule 7.2 shall be paid only once. Alliqua shall pay to CCT each such amount
within forty-five (45) days following the end of such Launch Year in which achievement of the applicable Milestone Event occurred.
If any Milestone Event is achieved and Alliqua has not yet made the prior Milestone Payment(s), all previous unpaid Milestone Payments
shall be due and payable together with the payment of the Milestone Payment for the first such subsequent Milestone Event achieved.

 

    	 

    	 

    

 

THE
COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL
PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED
IN THIS EXHIBIT WITH “*****”.

 

		4.	Performance under all other terms of the Agreement: Except as expressly amended hereby,
the Agreement shall remain in full force and effect as presently written, and the rights, duties, liabilities and obligations of
the Parties thereto, as presently constituted, will continue in full effect. This First Amendment is incorporated and made a part
of the Agreement between the Parties. This First Amendment, together with the Agreement, constitutes the entire agreement between
the Parties with respect to the subject matter contained therein, and together, supersede and replace any prior and/or contemporaneous
discussions, understandings, representations or agreements, whether written or oral, with respect to the subject matter thereof.

 

		5.	Counterparts: This First Amendment may be executed in two (2) or more counterparts, each
of which shall be deemed an original but all of which together shall constitute the same legal instrument. Facsimile or PDF execution
and delivery of this First Amendment by any Party shall constitute a legal, valid and binding execution and delivery of this First
Amendment by such Party. The Parties to this document agree that a copy of the original signature (including an electronic copy)
may be used for any and all purposes for which the original signature may have been used. The Parties agree they will have no rights
to challenge the use or authenticity of this document based solely on the absence of an original signature.

 

 

 

IN WITNESS WHEREOF,
each of the Parties has caused this First Amendment to be executed, as of the First Amendment Effective Date, by its duly authorized
officer or representative.

 

	
        ANTHROGENESIS CORPORATION

         

         

         

         

         

        By: /s/ Perry Karsen                 

         

         

        Name: Perry Karsen

         

        Title: Chief Executive Officer

         

         

         

         

         
	 	
        ALLIQUA BIOMEDICAL, INC.

        (formerly Alliqua, Inc.)

         

         

         

        By: /s/ Brian M. Posner             

         

         

        Name: Brian M. Posner

         

        Title: Chief Financial Officer

         

         

         

         

         

 

 

 

  

 

    	2

    	 

    

 

THE
COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL
PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED
IN THIS EXHIBIT WITH “*****”.

 

Schedule 7.2

Milestone Payments

 

	 	Milestone Event for Biovance 	Milestone Payment
	1	At such time as aggregate annual Net Sales for any rolling twelve month period equal or exceed [****]	[****]
	2	At such time as aggregate annual Net Sales for any rolling twelve month period equal or exceed [****]	[****]
	3	At such time as aggregate annual Net Sales for any rolling twelve month period equal or exceed [****]	[****]
	4	At such time as aggregate annual Net Sales for any rolling twelve month period equal or exceed [****]	[****]

 

 

	 	Milestone Event for ECMs	Milestone Payment
	5	510(k) or other Regulatory Clearance and/or Approval of ECM [****]	[****]
	6	510(k) or other Regulatory Clearance and/or Approval of ECM [****]	[****]
	7	510(k) or other Regulatory Clearance and/or Approval of ECM [****]	[****]
	8	At such time as aggregate annual Net Sales for any rolling twelve month period equal or exceed [****]	[****]
	9	At such time as aggregate annual Net Sales for any rolling twelve month period equal or exceed [****]	[****]
	10	At such time as aggregate annual Net Sales for any rolling twelve month period equal or exceed [****]	[****]
	11	At such time as aggregate annual Net Sales for any rolling twelve month period equal or exceed [****]	[****]

 

 

    	3Exhibit 10.2

 

THE
COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL
PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED
IN THIS EXHIBIT WITH “*****”.

 

SECOND AMENDMENT TO THE
SUPPLY AGREEMENT

 

This
Second Amendment (“Second Amendment”) to the Supply
Agreement dated November 14, 2013 (as
amended by the First Amendment to the Supply Agreement dated April 10, 2014) (collectively the Supply Agreement and First Amendment
hereinafter the “Agreement”), is effective as of September 26, 2014 (the “Second Amendment Effective
Date”), by and between Anthrogenesis Corporation, a Delaware corporation doing business as Celgene Cellular Therapeutics
(“CCT”), and Alliqua BioMedical, Inc., a Delaware corporation (formerly Alliqua, Inc., a Florida corporation)
(“Alliqua”). Alliqua and CCT may each be referred to as a “Party” or collectively be referred
to as the “Parties”.

 

WHEREAS Alliqua and CCT entered into the
Agreement;

 

WHEREAS both Parties now wish to amend
the terms of the Agreement as further described in this Second Amendment;

 

NOW and THEREFORE the Parties hereby
agrees as follows:

 

All capitalized terms used in this Second
Amendment shall have the meaning ascribed to them in the Agreement, except as otherwise expressly stated herein.

 

		1.	As of the Second Amendment Effective Date, Section 6.2 of the Agreement shall be deleted
in its entirety and replaced with the following:

 

6.2Additional CCT Representations
and Warranties. CCT represents and warrants to Alliqua that at the time each Manufactured Product is delivered to Alliqua such
Manufactured Product: (a) will meet the Specifications therefor; (b) will have been manufactured, stored and handled at CCT’s
facility, and tested in accordance with the applicable Law, Regulatory Clearances and/or Approvals, Specifications and cGTPs; (c)
will have a remaining shelf life no less than [****] of the shelf life set forth in the Regulatory Clearances and/or Approvals
therefor in the Territory; (d) will not be (i) adulterated, or (ii) manufactured, stored or handled at CCT’s facility, or
tested in a manner that violates the Act, or any other applicable Law; and (e) will pass to Alliqua free and clear of any security
interest, lien or other encumbrances.

 

		2.	Performance under all other terms of the Agreement: Except as expressly amended hereby,
the Agreement shall remain in full force and effect as presently written, and the rights, duties, liabilities and obligations of
the Parties thereto, as presently constituted, will continue in full effect. This Second Amendment is incorporated and made a part
of the Agreement between the Parties. This Second Amendment, together with the Agreement, constitutes the entire agreement between
the Parties with respect to the subject matter contained therein, and together, supersede and replace any prior and/or contemporaneous
discussions, understandings, representations or agreements, whether written or oral, with respect to the subject matter thereof.

 

		3.	Counterparts: This Second Amendment may be executed in two (2) or more counterparts, each
of which shall be deemed an original but all of which together shall constitute the same legal instrument. Facsimile or PDF execution
and delivery of this Second Amendment by any Party shall constitute a legal, valid and binding execution and delivery of this Second
Amendment by such Party. The Parties to this document agree that a copy of the original signature (including an electronic copy)
may be used for any and all purposes for which the original signature may have been used. The Parties agree they will have no rights
to challenge the use or authenticity of this document based solely on the absence of an original signature.

 

    	 

    	 

    

 

THE
COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL
PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED
IN THIS EXHIBIT WITH “*****”.

 

IN WITNESS WHEREOF,
each of the Parties has caused this Second Amendment to be executed, as of the Second Amendment Effective Date, by its duly authorized
officer or representative.

 

	
        ANTHROGENESIS CORPORATION

         

         

         

         

         

        By: /s/ Perry Karsen                

          

         

        Name: Perry Karsen

         

        Title: Chief Executive Officer

         

         

         

         

         
	 	
        ALLIQUA BIOMEDICAL, INC.

        (formerly Alliqua, Inc.)

         

         

         

        By: /s/ Brian M. Posner                

         

         

        Name: Brian M. Posner

         

        Title: Chief Financial Officer

         

         

         

         

         

 

 

    	2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}]]